Late-stage clinical pharmaceutical company Cinclus Pharma Holding AB (STO:CINPHA) on Thursday announced a strategic partnership and licensing agreement with Zentiva, a pharmaceutical company based in the Czech Republic, for the commercialisation and manufacturing of linaprazan glurate across Europe, including all EEA member states, the UK and Switzerland.

The total value of the deal amounts to EUR220m, including an upfront payment of EUR13m and a EUR5m milestone payment expected in 2026. Cinclus Pharma will also receive tiered double-digit royalties on net sales in Europe, beginning in the high teens and exceeding 20% at upper tiers.

Linaprazan glurate is a next-generation potassium-competitive acid blocker developed to treat severe erosive gastroesophageal reflux disease. The company plans to initiate its first Phase III trial of the therapy in the third quarter of 2025.

The global addressable market for this condition includes approximately 19 million patients, with 10 million across Europe and the United States.